Liraglutide for patients with non-alcoholic steatohepatitis
| العنوان: | Liraglutide for patients with non-alcoholic steatohepatitis |
|---|---|
| المؤلفون: | Patricia Ancel, Patrice Darmon, Anne Dutour, Bénédicte Gaborit |
| المساهمون: | Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU)-Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU) |
| المصدر: | Lancet Lancet, Elsevier, 2016, 387 (10036), pp.2378-9 The Lancet The Lancet, Elsevier, 2016, 387 (10036), pp.2378-9. ⟨10.1016/S0140-6736(16)30734-6⟩ The Lancet, Elsevier, 2016, 387 (10036), pp.2378-2379 The Lancet, Elsevier, 2016, 387 (10036), pp.2378-2379. ⟨10.1016/S0140-6736(16)30734-6⟩ Lancet, Elsevier, 2016, 387 (10036), pp.2378-9. ⟨10.1016/S0140-6736(16)30734-6⟩ |
| بيانات النشر: | HAL CCSD, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Incretins, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Weight loss, Internal medicine, medicine, Humans, In patient, ComputingMilieux_MISCELLANEOUS, business.industry, Liraglutide, Non alcoholic, General Medicine, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, Obesity, life style intervention, Female, Steatosis, medicine.symptom, Steatohepatitis, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug |
| الوصف: | 2378 www.thelancet.com Vol 387 June 11, 2016 hepatic steatosis is due to weight loss? Previous studies have found a direct eff ect of weight loss on hepatic steatosis. In the LEAN study, the liraglutide effect did not remain signifi cant after adjusting for weight loss. Changes in weight were not signifi cantly diff erent in patients with or without histological response to liraglutide. However, we would have expected that the authors present the eff ect of liraglutide on hepatic steatosis in patients with or without weight loss. If verified, the effect of liraglutide, independent of weight loss, would have been even more convincing. This distinction seems important because in patients with obesity and type 2 diabetes, bariatric surgery has shown benefi cial eff ects on hepatic steatosis, which are sustained in long-term studies, whereas weight stabilisation is often reported in patients chronically treated with glucagon-like peptide-1 receptor agonists. The LEAN study has brought new insight and given a new therapeutic option in non-alcoholic steatohepatitis. Further, larger studies with a longer duration are warranted to confi rm these results. |
| اللغة: | English |
| تدمد: | 0140-6736 1474-547X 0923-7577 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88b6225eacdc7e81301a37aa0cb65054Test https://hal.archives-ouvertes.fr/hal-01478310Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....88b6225eacdc7e81301a37aa0cb65054 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 01406736 1474547X 09237577 |
|---|